O ROURKE & COMPANY Inc Lowers Stock Position in Johnson & Johnson (NYSE:JNJ)

O ROURKE & COMPANY Inc lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 1.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 8,801 shares of the company’s stock after selling 115 shares during the period. O ROURKE & COMPANY Inc’s holdings in Johnson & Johnson were worth $1,426,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the business. Cordatus Wealth Management LLC lifted its position in shares of Johnson & Johnson by 1.7% in the 3rd quarter. Cordatus Wealth Management LLC now owns 31,913 shares of the company’s stock worth $5,172,000 after purchasing an additional 523 shares during the period. United Asset Strategies Inc. lifted its position in shares of Johnson & Johnson by 510.6% in the 3rd quarter. United Asset Strategies Inc. now owns 60,192 shares of the company’s stock worth $9,755,000 after purchasing an additional 50,334 shares during the period. Rosenberg Matthew Hamilton lifted its position in shares of Johnson & Johnson by 12.7% in the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,319 shares of the company’s stock worth $538,000 after purchasing an additional 374 shares during the period. Tilson Financial Group Inc. purchased a new stake in Johnson & Johnson during the third quarter valued at approximately $258,000. Finally, Tevis Investment Management lifted its position in Johnson & Johnson by 5.4% during the third quarter. Tevis Investment Management now owns 17,334 shares of the company’s stock valued at $2,809,000 after acquiring an additional 884 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.2 %

NYSE JNJ opened at $160.13 on Friday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The company has a market capitalization of $385.53 billion, a PE ratio of 23.17, a P/E/G ratio of 2.85 and a beta of 0.52. The company has a fifty day moving average of $163.31 and a 200 day moving average of $155.44.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period in the prior year, the company earned $2.66 earnings per share. The firm’s revenue was up 5.2% on a year-over-year basis. Research analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.10%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. The Goldman Sachs Group decreased their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Sanford C. Bernstein increased their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. TD Securities decreased their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Finally, TD Cowen decreased their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.93.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.